Y-Biologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Y-Biologics develops antibody-based medicines, laboratory-engineered proteins designed to target and block disease-causing molecules in the body, with a focus on cancer immunotherapy and other areas of unmet medical need.
It operates on two business models: licensing its drug candidates and platform technology to larger pharmaceutical companies, and providing contract research services to generate ongoing revenue. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company runs a pipeline of independently developed candidates alongside programs co-developed with partners, spanning formats such as bispecific antibodies and antibody-drug conjugates.
Summary is AI-generated and may contain errors · figures from DART filings
Y-Biologics in five facts
What does Y-Biologics do?
Y-Biologics develops antibody-based medicines, laboratory-engineered proteins designed to target and block disease-causing molecules in the body, with a focus on cancer immunotherapy and other areas of unmet medical need.
Where is Y-Biologics listed and in which sector?
Y-Biologics (Korean name: 와이바이오로직스) trades under KRX code 338840 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Y-Biologics?
Its market capitalisation was US$102.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Y-Biologics's latest annual revenue and operating profit?
For fiscal year 2025, Y-Biologics reported revenue of US$2.2M, an operating loss of US$24.7M and a net loss of US$24.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 49.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 20
- Report on securities held by executives/major shareholdersOct 15
- Report on securities held by executives/major shareholdersOct 15
- Report on securities held by executives/major shareholdersOct 14
- Report on securities held by executives/major shareholdersOct 14
- Report on large shareholdings (5% rule) (standard)Oct 1
- Grant of stock optionsOct 1
- Results of extraordinary shareholders' meetingSep 22
- Proxy solicitation reference documentSep 4
- Notice of general shareholders' meetingSep 4
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Y-Biologics reported separate results for FY2025: revenue of US$1.97M (−49.5% year on year), an operating loss of US$6.28M and a net loss of US$28.5M.
Earnings · Mar 12